A new sandwich enzyme-linked immunosorbent assay (S-ELISA) kit that uses raw (unprocessed) fetal bovine serum (FBS) as the testing sample was evaluated for upstream bovine viral diarrhea virus (BVDV) testing. Pooled FBS samples (n ϭ 84) were tested using the S-ELISA. Thirty serum samples originating from persistently infected (PI) calves that had been confirmed by virus isolation (VI) as BVDV positive and another 30 samples previously confirmed by VI as BVDV negative were also evaluated. Of the 84 field samples, the S-ELISA detected 13 (15.5%) BVDV-positive specimens. When these 13 positive samples were tested by VI and immunofluorescent assay, 11 (84.6%) were positive and 2 (15.4%) were negative. The S-ELISA was positive for all 30 PI samples (100%) and negative for all 30 negative samples (100%). These data indicate that the new kit is a relatively reliable diagnostic tool and can be considered for upstream detection of BVDVcontaminated raw FBS pools.
Bovine viral diarrhea (BVD) is recognized as one of the most economically important infectious diseases of cattle. The BVD virus (BVDV) is a single-stranded RNA virus and is a member of the Pestivirus genus in the Flaviviridae family. 2 The BVDVs are separated according to their biotype and genotype. On the basis of their growth characteristics in cell cultures, BVDV biotypes are classified into cytopathic (CP) and noncytopathic (NCP) biotypes. CP strains cause visual cytopathic effects (CPE), and NCP strains grow in cells without visual CPE. 2 Genotypes (types 1 and 2) are viruses with genetic variations detected by polymerase chain reaction. 2 An important consequence of BVDV infection of a pregnant cow is in utero fetal infection. When infection occurs with a NCP strain during 90-120 days of gestation, the birth of persistently infected (PI) calves is common. 4, 9 The PI cattle disseminate large amounts of BVDV into the environment throughout their lives and, therefore, represent a mechanism by which the virus persists and spreads among cattle herds. Blood collection from infected fetuses is the main source of fetal bovine serum (FBS) contamination. Virus testing is a very important measure to assure the biosafety of FBS and other animal origin products. Traditionally, virus testing of final (processed) FBS products, including testing for BVDV, is performed in accordance with 9 Code of Federal Regulations (9CFR; 1999, Code of Federal Regulations, booklet 9, Sections 113.46 and 113.47). Serum has been shown to be an excellent diagnostic sample for BVDV because PI cattle have large amounts of BVDV (usually 10 3 -10 5 CCID 50 /ml) in their serum. 1, 3 One PI fetus can theoretically contaminate thousands of liters of FBS. It is therefore no surprise that a high percentage of commercially available FBS is contaminated with BVDV. In 1 study, 20.6% of raw FBS and 49% of commercially available FBS lots were contaminated with BVDV. 1 Furthermore, the BVDV is very stable in serum, surviving at room temperature for at least 7 days. 8 From Life Technologies, Grand Island Cell Culture R&D, PO Box 68, Grand Island, NY 14072.
Received for publication June 5, 2000. The PI animals are, by definition, immunotolerant to BVDV and may not develop anti-BVDV antibodies. However, the prevalence of BVDV antibody-positive adult animals in the cattle population is high, typically about 70%. 5 The objective of this work was to evaluate a new commercial sandwich enzyme-linked immunosorbent assay (S-ELISA) kit using raw, unprocessed FBS as the test sample for BVDV detection and for identifying BVDV-positive lots at the beginning of the serum manufacturing process (upstream).
A total of 84 FBS pools were tested using the new commercial kit. a Blood was collected from 6-8-month-old bovine fetuses, and serum was separated by centrifugation following blood coagulation. Pools of approximately 3 liters of clarified FBS were made from the serum collected from 5-10 fetuses. A sample from each of 84 pools was tested for BVDV antigen detection by S-ELISA, and further confirmed by cell culture virus isolation (VI) followed by direct fluorescent antibody (FA) antigen detection. Additionally, 30 positive samples from PI calves and a group of 30 negative samples from healthy young animals were used as controls in this study. These controls had been previously confirmed to be BVDV positive or negative, respectively, by VI and direct FA staining.
The commercial S-ELISA kit a was used for detecting BVDV antigen in sera following the manufacturer's instructions. The result interpretation was optimized taking into consideration pooled FBS samples. All incubation steps were performed at room temperature. The 96-well microtiter strip plates that had been precoated with a capture antibody were prewetted with ELISA wash buffer, and 200 l of test serum was added to each well. Along with the test samples, 1 known positive and 1 known negative sample, supplied in the kit, were included in each run as controls. After incubation for 1 hour, the plates were washed, and 100 l/well of detector reagent was added, followed by incubation for 1 hour at room temperature. In the next stage, the plates were washed, and 100 l/well of enzyme conjugate was added, followed by incubation for 1 hour at room temperature. After a final 1-hour incubation, the substrate was added (100 l/well), and the plates were incubated in the dark for 10 minutes. The color reaction was stopped by adding 100 l/well of stopping solutions. Color intensity was measured using a spectrophotometer at 450 nm wavelength. The optical density (OD) values of the positive control and test samples were blank corrected by subtracting the OD value of the negative control. OD values of Ͻ0.49 were considered BVDV negative, and values Ն0.5 were considered BVDV positive.
All samples tested in the S-ELISA were further evaluated by VI in primary bovine testicle (BT) cell culture using the following procedure. A 1-ml aliquot of serum was added into duplicate T-25 tissue culture flasks of primary BT cells. The serum was adsorbed for 1 hour at 37 C, and then serumfree cell culture medium b was added (9 ml) to the flask without removing the previously added serum. After 5 days of incubation at 37 C with 5% CO 2 (the first passage), the cells were trypsinized and split 1:3. Samples of cells were tested for BVDV antigen using monoclonal antibodies c specific for BVDV. The FA test was repeated in 2 days (the second passage) to confirm the positive results. For the negative samples, the testing was continued for a third blind passage, followed by the FA staining.
Thirteen of 84 (15.5%) raw FBS pools reacted positively in the S-ELISA. Eleven of 13 (84.6%) positive samples detected by S-ELISA were positive by the VI assay in primary BT cells. Two of 13 (15.4%) ELISA-positive samples were negative by VI. This indicates a possibility of finding a higher percentage of positive specimens by S-ELISA than by VI, possibly because the ELISA may detect the antigenic determinants of both live and dead virus particles, whereas the cell culture can only detect live virus capable of multiplication and further amplification through blind passages. Therefore, the 15.5% of the FBS raw pools that were positive by S-ELISA in this study can be considered accurate, even though these results slightly disagree with the VI findings. None of the S-ELISA-negative samples were positive by VI. Additionally, 30 of 30 (100%) BVDV-positive calf samples, as previously determined by VI, reacted positively in the S-ELISA. Furthermore, all 30 (100%) BVDV-negative calf serum samples (as determined by VI) were also negative in the S-ELISA.
Comparing performances of the 2 tests (VI and S-ELISA) on the 30 positive and 30 negative specimens, there was no apparent disagreement between the 2 procedures. In these 2 groups of positive and negative samples, the relative sensitivity of the S-ELISA can reach 100%, and the relative specificity is also 100%. These observations, however, should be taken with caution when testing FBS pools because results may vary dependent upon the pool size, virus load, and the virus dilution factor in positive specimens.
FBS and other biologic products of animal origin can be contaminated with various adventitious agents. Viruses are of particular safety concern because of their biophysical properties, i.e., composition, size, and morphology. Proper processing during manufacturing can minimize the risk of these agents contaminating a final product such as FBS. Final product testing for adventitious agents, including viruses, can further reduce the risk of introducing a contaminated product into a production facility or a research project.
Previous studies have shown that serum is an excellent diagnostic specimen for the detection of BVDV because of the high stability of the virus in serum. 6, 7 This remarkable stability of BVDV in serum and the ease of using serum for whole-herd testing indicate that serum should be the target clinical specimen for BVDV testing in PI cattle.
In this study, 3-liter pools of raw FBS were used, instead of clinical specimens, for product testing at the early stage of FBS manufacture. This is the first report on BVDV testing of raw FBS using this new ELISA kit. The results presented here indicate that FBS pools can be used as appropriate specimens for BVDV screening. However, the data obtained must be interpreted with caution; the pool size, virus load, and virus dilution factor must be considered. The implementation of the S-ELISA for the upstream BVDV testing of raw FBS pools does not eliminate the need for the thorough virus testing of the final FBS products downstream.
Although the S-ELISA cannot replace the full 9CFR virus testing on the final FBS product, it can be effectively implemented at the early manufacturing steps to identify and segregate positive sublots. This approach would significantly reduce the percentage of contaminated final FBS lots in commercial use.
